Research & Development at Novartis The Novartis Pharmaceuticals clinical pipeline holds a broad stream of 140 future projects including both new molecular entities and additional indications or formulations for marketed products. Our pipeline has consistently being ranked by experts as one of the strongest in the industry. Our scientists focus on diseases for which medical need remains unmet and strive to improve the drug discovery process with an approach that integrates novel concepts and tools across multiple disease areas.
Data from five real-world evidence (RWE) and observational studies being conducted in North America, Latin America and Europe provide extensive cumulative insights for Cosentyx (secukinumab) clinical practice among more than 13,000 patients [1-6] - The studies report on the real-world sustained
Results from a Phase IIb dose-finding study show an average complete response rate of 42% for doses 240 mg and 72 mg ligelizumab at Week 12 compared with 26% for those taking 300 mg Xolair's dose (omalizumab) - Complete control of hives achieved by 51% and 42% of patients treated with ligelizum
Phase III PREVENT study met 52-week primary endpoint of ASAS40, showing a sustained response in patients with non-radiographic axial spondyloarthritis (nr-axSpA) - Novartis plans FDA submission for nr-axSpA, having submitted to EMA previously.
Once-daily QMF149 demonstrated superior improvement in lung function versus mometasone furoate, meeting primary endpoint PALLADIUM is part of Phase III PLATINUM clinical development program, which evaluates inhaled combinations QMF149 and QVM149 - Novartis is aiming to reimagine inhaled asthma
In MONALEESA-3, Kisqali plus fulvestrant achieved statistically significant overall survival benefit vs.
Early combination treatment strategy with vildagliptin (Galvus ) and metformin was superior to standard of care in newly diagnosed type 2 diabetes patients , - The landmark VERIFY study is the first to investigate the long-term clinical benefits of this early combination strategy in type 2 diab
In two head-to-head clinical trials, patients on Beovu (brolucizumab) achieved vision gains that were non-inferior to aflibercept at year one with longer treatment intervals in a majority of patients , - Beovu demonstrated greater reductions in central subfield thickness (CST, a key indicator o
Older patients (= 2 years and < 5 years) achieved a mean increase of 5.9 points from baseline in HFMSE scores, nearly double the clinically meaningful threshold (at a mean duration of follow-up time of 9.3 months) Untreated SMA Type 2 patients historically experience declining HFMSE scores over time, will never walk without support and often need a wheelchair.
Multiyear alliance underpins the Novartis commitment to leverage data & Artificial Intelligence (AI) to transform how medicines are discovered, developed and commercialized Novartis to establish AI innovation lab to empower its associates to use AI across the business Joint research activitie
Once-daily QVM149 demonstrated statistically significant improvement in lung function versus QMF149, meeting primary endpoint , - IRIDIUM is largest study in Phase III PLATINUM clinical development program, which evaluates inhaled combinations QVM149 and QMF149 - Novartis is aiming to reimagi
New interim data from SPR1NT study supports critical importance of early intervention in pre-symptomatic SMA patients, leading to age-appropriate major milestone gain Updated results from global STR1VE study demonstrate that Zolgensma (onasemnogene abeparvovec-xioi) has significant therapeutic be
Phase III PREVENT study met 16-week primary endpoint of ASAS40 in patients with active non-radiographic axial spondyloarthritis (nr-axSpA). All secondary endpoints were also met - Novartis has submitted to EMA for approval in nr-axSpA, which would be the fourth indication for Cosentyx.
LinkMedicine and Life Sciences
Last job offers
- Business/Economics - 15.10
Wissenschaftliche/r Mitarbeiter/in (100 %)
- Administration - 14.10
Mitarbeiterin / Mitarbeiter Grants Office (80-100 %)
- Law - 12.10
Professur (Associate/Full Professor/in) für Wirtschaftsstrafrecht, Compliance und Digitalisierung (100 %)
- Social Sciences - 10.10
Wissenschaftliche/r Mitarbeiter/in (50−60 %) Schwerpunkt Organisationaler Wandel
- Health - 10.10
Postdoc/ Senior Researcher with Strong Quantitative Skills for Health Economics and Healthcare Management Research
- Life Sciences - 10.10
Become a Principal Investigator at CeMM
- Health - 15.10
Postdoc Intestinal host-microbe interactions (1.0 FTE)
- Health - 15.10
Adjunct Professor / Associate Professor of Medicine (Ear, Nose and Throat)